PATAFPrimary prevention of Arterial Thrombo-embolismin patients with non-valvular Atrial Fibrillation
Ongoing trial |
| Authors: |
|
| Titles: |
(a) Primary preventive effects of anticoagulants and acetylsalicylic acid on arterial thromboembolism in patients with nonvalvular atrial fibrillation in general practice (PATAF)
(b) Primary prevention of arterial thrombo- embolism in non-rheumatical atrial fibrillation. Results of the PATAF study |
| References: |
(a) Stroke 1994;25:1318
(b) J Am Coll Cardiol 1998;31(suppl A):344A |
| Disease: |
Non-valvular atrial fibrillation |
| Purpose: |
To compare the efficacy of warfarin in two different dosages and aspirin for the primary prevention of ischaemic stroke and systemic thromboembolism in patients with non-valvular atrial fibrillation |
| Study Design: |
Randomised, open |
| Follow-up: |
Mean 2.7 years |
| Patients: |
729 patients, aged > 60 years, with sustained or intermittent atrial fibrillation |
| Treatmentregimen: |
Oral anticoagulants to target international normalised ratio 2.5-3.5, or 1.1-1.6, or aspirin, 150 mg/day |
| Results: |
The overall incidence of vascular death, stroke, systemic thromboembolism, or major haemorrhage was 2%. In patients with a contraindication to oral anticoagulants, the incidence was 10% in the aspirin group and in the low-dose oral anticoagulant group. The main trial results are not yet published |
